CV Sciences (CVSI) Stock Analysis — October 2026
Executive Summary
CV Sciences (OTC: CVSI) is a cbd / hemp company currently priced at $0.0083 per share with a market capitalization of $1.9M. The company generates trailing twelve-month revenue of $12.7M with a gross margin of 49.1% and year-over-year revenue growth of -14.90%. The stock trades on the OTC exchange in the United States market, and is positioned as a small-cap player within the cannabis sector.
Key Takeaways
CV Sciences has a market cap of $1.9M, making it a small-cap cannabis company listed on the OTC.
Trailing twelve-month revenue is $12.7M with year-over-year growth of -14.9%. Declining revenue is a concern that warrants attention.
The company's gross margin stands at 49.1%. This healthy margin provides a solid foundation for reinvestment and path to bottom-line profitability.
CV Sciences holds $266.0K in cash against $18.0K in debt, resulting in a net cash position of $248.0K and an estimated 6.5 months of cash runway.
The stock trades at a P/S ratio of 0.15x and EV/Revenue of 0.13x. Relatively low multiples could indicate an undervalued opportunity.
At $0.0083, the stock trades at 1% of its 52-week range ($0.0071 – $0.10). Trading near yearly lows could present value for contrarian investors.
CV Sciences Company Overview
CV Sciences (OTC: CVSI) is a CBD and hemp company currently trading at $0.0083 per share with a market capitalization of $1.9M. The stock declined +10.80% in the most recent trading session on volume of 576.9K shares. CV Sciences is headquartered in the United States and employs approximately 0 people. As a participant in the cbd / hemp segment, the company operates within one of the most dynamic and rapidly evolving sectors of the North American economy.
On the revenue front, CV Sciences generated $12.7M in trailing twelve-month (TTM) revenue, reflecting year-over-year growth of -14.9%. This growth rate is trailing the CBD sector average of +1.6%. CV Sciences maintains a moderate gross margin of 49.1%, indicating the company is generating positive gross profit on its sales, though operational profitability may still be a work in progress. Revenue trends in the cannabis industry are closely watched by analysts, as the sector continues to navigate pricing compression, oversupply dynamics in certain markets, and the ongoing burden of IRS Section 280E, which prevents cannabis businesses from deducting ordinary business expenses at the federal level.
Financial Analysis
CV Sciences generated $12.7M in trailing twelve-month revenue, reflecting year-over-year growth of -14.90%. The company's gross margin of 49.1% translates to approximately $6.3M in gross profit over the trailing twelve months. This margin profile places CV Sciences among the more profitable operators in the cannabis sector, demonstrating strong pricing power and cost management.
Revenue momentum is a critical metric for cannabis companies, as the industry continues to evolve through shifts in consumer demand, regulatory changes, and competitive dynamics. CV Sciences's revenue decline of -14.90% is a notable concern that may be attributable to market headwinds, competitive pressure, pricing compression, or strategic transitions. Investors should closely monitor whether this trend stabilizes or accelerates in coming quarters. The cannabis industry's profitability dynamics are heavily influenced by IRS Section 280E, which prevents plant-touching operators from deducting ordinary business expenses for federal income tax purposes, effectively creating tax rates that can exceed 70% of gross profit.
Valuation Analysis
From a valuation perspective, CV Sciences trades at a price-to-sales (P/S) ratio of 0.15x, which is below the sector median of 1.38x, which could indicate the stock is undervalued relative to peers or that the market has concerns about the company's growth trajectory. The enterprise value-to-revenue (EV/Revenue) multiple stands at 0.13x. Cannabis stock valuations have compressed significantly from their 2021 highs, and current multiples reflect a more mature market environment where investors demand clear paths to profitability. For context, the broader CBD sector contains 7 publicly traded companies tracked by Cannabismarketcap, and CV Sciences's valuation should be considered within the context of its specific growth profile and competitive positioning.
At a price-to-sales ratio of 0.15x and an enterprise value-to-revenue multiple of 0.13x, CV Sciences's valuation reflects the market's current assessment of the company's growth potential and risk profile. Enterprise value — calculated as market capitalization plus total debt minus cash — stands at approximately $1.6M, providing a more complete picture of the company's total valuation when accounting for balance sheet items. Investors should compare these multiples against both direct sector peers and historical ranges to determine whether CVSI is trading at a premium or discount.
Balance Sheet Deep Dive
The company holds a net cash position of $248.0K, with $266.0K in cash and equivalents against $18.0K in total debt. This provides a financial cushion of approximately 6.5 months of operating runway at current burn rates. Access to capital remains a persistent challenge for cannabis companies, particularly plant-touching operators that are excluded from traditional banking services and institutional lending. Many cannabis companies have turned to sale-leaseback transactions, private placements, and at-the-market (ATM) equity offerings to fund operations. CV Sciences's balance sheet should be evaluated with these industry-specific constraints in mind.
CV Sciences maintains a net cash position of $248.0K, which represents a meaningful financial cushion. With $266.0K in cash and equivalents against $18.0K in total debt, the company has an estimated 6 months of operating runway at the current rate of cash consumption. This runway provides management with flexibility to pursue organic growth initiatives, evaluate strategic M&A opportunities, and navigate the capital-constrained cannabis industry without immediate pressure to raise dilutive equity capital.
The company's annual share dilution rate is not reported in our data. With 225.8M shares currently outstanding, any additional equity issuance directly impacts per-share metrics including earnings per share, book value per share, and ownership percentage.
CBD / Hemp Sector Context
Within the CBD / Hemp sector, CV Sciences ranks #6 out of 7 companies by market capitalization, commanding a 2.2% share of the sector's total market cap of $83.6M. CBD and hemp companies focus on the production and distribution of cannabidiol products and industrial hemp. Following the 2018 Farm Bill that legalized hemp-derived CBD at the federal level, this sub-sector has grown rapidly in consumer goods, wellness, and pet care markets. The largest company in the sector by market cap is Charlotte's Web Holdings (CWBHF) at $64.6M, followed by PharmaCielo (PCLOF) at $7.5M.
By revenue, CV Sciences ranks #3 of 3 sector companies that report revenue, with $12.7M in trailing twelve-month sales. The sector's top revenue generator is Charlotte's Web Holdings at $46.8M. CV Sciences's gross margin of 49.1% compares to a sector average of 49.7%, placing it below the peer group midpoint. Revenue growth of -14.9% year-over-year reflects challenges that may include market headwinds, competitive pressure, or strategic transitions.
CV Sciences occupies a smaller position within the CBD / Hemp sector. With a P/S ratio of 0.15x and an EV/Revenue of 0.13x, the company's valuation reflects the market's assessment of its growth potential and risk profile relative to the 6 other tracked peers. Investors should evaluate CV Sciences alongside its direct sector competitors to understand relative value and operational momentum.
Historical Price Performance
CV Sciences (CVSI) currently trades at $0.0083, which places the stock at approximately 1% of its 52-week trading range. Over the past twelve months, CVSI has traded as high as $0.10 and as low as $0.0071, representing a 1308.5% spread between the yearly high and low. The current price sits 91.7% below the 52-week high and 16.9% above the 52-week low. This range provides important context for understanding the stock's recent volatility and where current levels fall within the broader price history.
In the most recent trading session, CVSI fell +10.80% from a previous close of $0.0093 to $0.0083, on volume of 576.9K shares. This negative session represents a significant single-day move that may have been driven by company-specific news, sector-wide sentiment, or broader market dynamics. The stock has 225,829,128 shares outstanding, giving it a fully diluted market capitalization that investors should factor into their analysis alongside the current $1.9M market cap figure.
Cannabis stocks have historically exhibited significant price volatility driven by regulatory developments, earnings surprises, and shifts in market sentiment toward the sector. CVSI is trading in the lower portion of its 52-week range, which could represent a value opportunity for contrarian investors, or may reflect deteriorating fundamentals that warrant caution. Historical price levels should be considered alongside fundamental data — including revenue trends, margin improvement, and balance sheet health — to form a complete investment thesis.
Investment Thesis
A balanced framework for evaluating CV Sciences (CVSI) as a potential investment, considering both the upside catalysts and downside risks based on the company's current financial data and industry positioning.
Revenue stabilization and potential for operational improvements could reignite top-line growth. With TTM revenue of $12.7M, even modest gains in market share or pricing power could meaningfully impact the company's financial trajectory and investor sentiment toward CVSI.
Industry-leading gross margin of 49.1% provides a substantial cushion for reinvestment in growth initiatives, debt reduction, and eventual bottom-line profitability. This margin profile suggests strong pricing power and operational efficiency relative to cannabis peers.
Net cash position of $248.0K provides financial flexibility for strategic acquisitions, organic expansion, and weathering industry downturns. With approximately 6 months of cash runway, CV Sciences has a meaningful buffer to execute on its business plan without immediate dilutive capital raises.
Declining revenue of -14.90% year-over-year raises concerns about CV Sciences's competitive positioning and demand trends. Revenue contraction in a growing industry could signal market share losses, pricing pressure, or execution challenges that may persist in the near term.
Cannabis companies continue to face restricted access to traditional banking, institutional capital, and federal bankruptcy protections. These structural disadvantages increase the cost of capital and limit CV Sciences's financial flexibility compared to companies in federally legal industries, creating an uneven competitive landscape.
Regulatory uncertainty remains the single largest risk for CV Sciences and all cannabis investments. Federal prohibition in the United States creates ongoing challenges including Section 280E tax burdens, limited interstate commerce, and the risk of enforcement actions. State-level regulatory changes, licensing moratoriums, and social equity requirements add additional layers of unpredictability that can materially impact the company's operations and growth plans.
Risk Factors
Key risks that investors should consider before investing in CV Sciences (CVSI). This is not an exhaustive list, and investors should conduct their own due diligence.
Regulatory & Legal Risk
Cannabis remains a Schedule I controlled substance under federal law, creating fundamental legal uncertainty for CV Sciences and all plant-touching cannabis operators. Changes in federal enforcement policy, state regulatory frameworks, or local ordinances could materially impact the company's operations, licensing, and financial performance. The evolving patchwork of state regulations creates compliance complexity and limits the ability to operate across state lines.
Balance Sheet & Liquidity Risk
With $266.0K in cash against $18.0K in total debt and an estimated 6 months of cash runway, CV Sciences faces potential liquidity constraints. The company may need to secure additional financing through equity raises (which dilute shareholders), debt issuance (which increases financial risk), or asset sales (which may reduce operational capacity). Cannabis companies' limited access to traditional banking further constrains available financing options.
Section 280E Tax Burden
Under IRS Section 280E, cannabis businesses are prohibited from deducting ordinary business expenses for federal income tax purposes. This effectively results in tax rates that can exceed 70% of gross profit for plant-touching operators, significantly reducing cash flow available for reinvestment and debt service. While potential rescheduling could eliminate this burden, the timeline and outcome remain uncertain, and CV Sciences's profitability metrics should be evaluated with this tax overhang in mind.
Market & Competition Risk
The cannabis industry faces pricing pressure from oversupply in mature markets, competition from the illicit market (which avoids regulatory costs and taxation), and evolving consumer preferences. CV Sciences competes for market share against both established operators and well-funded new entrants. Price compression in key markets has squeezed margins across the industry, and any worsening of these trends could materially impact the company's revenue and profitability outlook.
Frequently Asked Questions
Common questions about CV Sciences (CVSI) stock, answered with real-time data from Cannabismarketcap.
What is CV Sciences's (CVSI) stock price today?
CV Sciences (CVSI) stock is currently trading at $0.0083 per share on the OTC exchange. This represents a daily decline of -10.80% ($0.0010) from the previous closing price of $0.0093. Over the past 52 weeks, CVSI has traded between a low of $0.0071 and a high of $0.10, placing the current price at approximately -92% from its annual high. The stock has a market capitalization of $1.9M, making it a notable cannabis companies tracked by Cannabismarketcap. CV Sciences operates in the CBD sector, serving the broader cannabis industry.
What is CV Sciences's market capitalization?
CV Sciences (CVSI) has a current market capitalization of $1.9M, calculated by multiplying its 225.8M shares outstanding by the current stock price of $0.0083. Market capitalization is a key measure of a company's total equity value as perceived by the public market, and it places CV Sciences among the small-cap cannabis companies tracked on Cannabismarketcap. For context, the enterprise value (market cap plus debt minus cash) stands at $1.6M, which accounts for the company's balance sheet structure. Investors often use market cap alongside revenue and profitability metrics to assess relative valuation within the cannabis sector.
Is CV Sciences profitable?
CV Sciences (CVSI) currently reports a gross margin of 49.1%, which means the company retains 49.1 cents of every revenue dollar after direct costs of goods sold. On trailing twelve month revenue of $12.7M, this translates to an estimated gross profit of approximately $6.3M. Profitability is a critical factor in the cannabis industry, where many companies are still investing heavily in growth and regulatory compliance. Investors should review the full income statement, cash flow trends, and operating expense breakdown on Cannabismarketcap for a complete picture of CV Sciences's financial health.
What is CV Sciences's annual revenue?
CV Sciences (CVSI) reports trailing twelve month (TTM) revenue of $12.7M, reflecting the total sales generated by the company over the most recent four quarters. Revenue has changed -14.90% year-over-year, reflecting a contraction in top-line performance relative to the prior period. The current price-to-sales ratio is 0.15x, which means investors are paying $0.15 for every $1 of annual revenue — a relatively low valuation in the context of the cannabis sector. Revenue is one of the most closely watched metrics for cannabis companies, as many are still scaling operations in a rapidly evolving regulatory environment. View the full income statement and quarterly revenue breakdown on Cannabismarketcap for detailed trend analysis.
What are CV Sciences's key financial metrics?
CV Sciences (CVSI) reports several important financial metrics that investors track closely. The company has a market capitalization of $1.9M, trailing twelve month revenue of $12.7M, and a gross margin of 49.1%. CV Sciences holds $266.0K in cash and equivalents against $18.0K in total debt. Total debt equals 0.01x market capitalization. The price-to-sales ratio stands at 0.15x, while the enterprise value to revenue multiple is 0.13x. With 225.8M shares outstanding, investors should consider both the fundamental financial performance and share structure when evaluating CVSI.
What exchange is CVSI listed on?
CV Sciences trades under the ticker symbol CVSI on the OTC exchange, and the stock is denominated in US dollars (USD). Shares can typically be purchased through most standard brokerage accounts, though some brokers may charge additional fees for OTC-listed securities. The stock sees average daily trading volume of approximately 576.9K shares, which is an important consideration for liquidity and the ability to enter or exit positions without significant price impact.
What sector is CV Sciences in?
CV Sciences is classified as a CBD and hemp company, meaning it specializes in cannabidiol (CBD) products derived from hemp, which are legal at the federal level under the 2018 Farm Bill. The CBD sector is a key segment of the cannabis market, and investors often compare companies within the same sector to identify relative outperformers. You can compare CVSI with other CBD stocks on Cannabismarketcap's sector page to see how it ranks on metrics like market cap, revenue, and margins.
What is CV Sciences's gross margin?
CV Sciences (CVSI) has a gross margin of 49.1%, which represents the percentage of revenue the company retains after paying for the direct cost of goods sold. On trailing twelve month revenue of $12.7M, this translates to an estimated gross profit of approximately $6.3M. Gross margin is a critical profitability indicator in the cannabis industry, where companies face unique cost pressures from regulatory compliance, testing requirements, and the tax burden of IRC Section 280E (which prevents cannabis companies from deducting standard business expenses). A moderate gross margin like CV Sciences's suggests the company has pricing power and operational efficiency relative to peers.
How does CVSI compare to other cannabis stocks?
You can compare CV Sciences (CVSI) side-by-side with any cannabis stock on Cannabismarketcap using the dedicated comparison tool. Key comparison metrics include market cap ($1.9M), trailing twelve month revenue ($12.7M), gross margin (49.1%), price-to-sales ratio (0.15x). CV Sciences sits in the CBD sector, so the most relevant peer comparisons would be against other CBD companies, though cross-sector comparisons can also reveal interesting insights about relative valuation. Visit the rankings page to see where CVSI stands across all cannabis companies on metrics like revenue growth (-14.90% YoY), cash position ($266.0K), and employee count (N/A).
What is CVSI's 52-week trading range?
CV Sciences (CVSI) has traded between a 52-week low of $0.0071 and a 52-week high of $0.10, with the current price of $0.0083 sitting approximately -92% from the annual high. This range represents a spread of $0.0929 (1308% from low to high), which reflects the volatility the stock has experienced over the past year. The 52-week range is a commonly used technical indicator that helps investors understand whether a stock is trading near the top or bottom of its recent range, and it can inform decisions about entry and exit points. Cannabis stocks in general tend to exhibit higher volatility than broader market indices due to evolving regulations and market sentiment.
How does CV Sciences's valuation compare to cannabis industry peers?
CV Sciences (CVSI) is valued at a market capitalization of $1.9M with a price-to-sales ratio of 0.15x, and an enterprise value of $1.6M. The EV/Revenue multiple of 0.13x provides a debt-adjusted view of valuation relative to sales, which is particularly important for comparing companies with different capital structures. In the cannabis industry, valuations can vary significantly depending on sector (MSO, LP, Ancillary, etc.), growth rate, and path to profitability. CV Sciences's current revenue trajectory of -14.90% YoY may result in a lower valuation relative to faster-growing peers. Investors can use the Cannabismarketcap rankings and comparison tools to benchmark CVSI against specific competitors on valuation multiples, growth rates, and profitability.
What is CV Sciences's enterprise value?
CV Sciences (CVSI) has an estimated enterprise value (EV) of $1.6M, which is calculated by taking the market capitalization of $1.9M, adding total debt of $18.0K, and subtracting cash and equivalents of $266.0K. Enterprise value is widely considered a more comprehensive measure of a company's total value than market cap alone because it accounts for the capital structure, including debt obligations and available liquidity. The resulting EV/Revenue ratio of 0.13x allows for an apples-to-apples comparison with peers regardless of differences in leverage. For cannabis companies in particular, where balance sheet health varies dramatically, enterprise value provides a more accurate picture of acquisition cost and relative valuation.
Is CV Sciences stock overvalued or undervalued?
Determining whether CV Sciences (CVSI) is overvalued or undervalued requires analyzing multiple valuation metrics in context. The current price-to-sales ratio of 0.15x is relatively low for a cannabis company, which could suggest the stock is undervalued or that the market has concerns about future growth. The stock is currently trading at $0.0083, which is -92% from its 52-week high of $0.10, with a gross margin of 49.1% and revenue growth of -14.90% YoY. Investors should consider the company's enterprise value of $1.6M, its cash position of $266.0K, and the broader cannabis industry outlook when forming a valuation opinion. Cannabismarketcap provides all the data needed for a thorough analysis, but this information should not be considered investment advice.
What are the risks of investing in CV Sciences?
Investing in CV Sciences (CVSI) carries several risks that investors should carefully consider. First, the cannabis industry remains federally illegal in the United States, creating regulatory uncertainty that can impact stock prices, banking access, and tax obligations (notably IRC Section 280E). Second, CV Sciences's balance sheet shows $18.0K in total debt against $266.0K in cash, with an estimated cash runway of approximately 6 months at the current burn rate, which investors should monitor for dilution risk or liquidity concerns. Additionally, the stock has shown a 52-week range of $0.0071 to $0.10, reflecting meaningful price volatility. As with all cannabis stocks, investors face risks from changing state regulations, competitive pressures, and the evolving legal landscape. This information is for educational purposes only and is not investment advice.
What is CV Sciences's cash position and debt level?
CV Sciences (CVSI) holds $266.0K in cash and equivalents on its balance sheet, set against $18.0K in total debt. This gives the company a net cash position of $248.0K. At the current rate of cash usage, the company has an estimated cash runway of approximately 6 months before needing additional financing, which could come from operations, debt, or equity issuance. Balance sheet strength is especially important in the cannabis industry, where companies often face limited access to traditional banking and capital markets. Investors should track these metrics over time on Cannabismarketcap to identify trends in cash consumption and debt management.
How many shares outstanding does CV Sciences have?
CV Sciences (CVSI) currently has 225.8M shares outstanding, which when multiplied by the current stock price of $0.0083 gives the company its market capitalization of $1.9M. Share count is important because all per-share metrics (earnings per share, book value per share, etc.) are directly impacted by changes in shares outstanding. Cannabis companies frequently issue new shares to raise capital, so monitoring dilution trends on Cannabismarketcap is recommended for long-term investors.
Does CV Sciences pay a dividend?
Most cannabis companies, including CV Sciences (CVSI), do not currently pay dividends. The cannabis industry is still in a growth phase, and companies typically reinvest available capital into expanding operations, securing new licenses, building out retail and cultivation infrastructure, and navigating complex regulatory requirements. Additionally, the IRC Section 280E tax burden significantly reduces the free cash flow available for shareholder distributions. Investors in cannabis stocks should generally expect returns to come from capital appreciation rather than dividend income. If CV Sciences initiates a dividend in the future, it would be reported in their SEC filings and reflected on Cannabismarketcap.
How can I research CV Sciences stock before investing?
To research CV Sciences (CVSI) before investing, start with the company overview on Cannabismarketcap, which provides current price ($0.0083), market cap ($1.9M), and key financial metrics. Next, review the full financial statements page for quarterly revenue trends, margins, and balance sheet details. Check the analyst ratings page for Wall Street consensus and price targets, and the technical analysis page for chart patterns and momentum indicators. Compare CVSI against sector peers using the comparison tool to understand relative valuation. Review recent news coverage for regulatory developments or corporate events. Finally, read the investment analysis page for a comprehensive deep-dive. Cannabis investing carries unique risks including federal illegality, regulatory uncertainty, and limited banking access — always conduct thorough due diligence before making any investment decision.
What does CV Sciences's market cap of $1.9M mean?
CV Sciences's market capitalization of $1.9M represents the total market value of all its outstanding shares (225.8M shares multiplied by the current stock price of $0.0083). Market cap is the primary measure investors use to classify companies by size: small-cap companies (under $100M) like CV Sciences may offer higher growth potential but come with greater risk and lower liquidity. In the cannabis sector, market cap is especially important because it determines index weighting, institutional investment eligibility, and often correlates with the company's operational scale and geographic reach. CV Sciences currently ranks # among cannabis stocks tracked on Cannabismarketcap.
What regulatory risks does CV Sciences face?
CV Sciences (CVSI), like all cannabis companies, faces significant regulatory risks that investors should understand. At the federal level, cannabis remains a Schedule I controlled substance in the United States, which restricts banking access, prevents standard business expense deductions under IRC Section 280E, and creates legal uncertainty. CV Sciences is subject to the evolving regulatory landscape across the jurisdictions where it operates. Potential catalysts include federal rescheduling (which could ease 280E burdens), the SAFE Banking Act (which would improve banking access), and individual state legalization events. Conversely, regulatory setbacks such as license moratoriums, increased enforcement, or unfavorable tax policy changes pose downside risks. Investors should monitor legislative developments closely using Cannabismarketcap's news and legalization tracker.
More CVSI Research & Data
CVSI price, chart & key stats
Revenue, earnings & balance sheet
Quarterly earnings & EPS trends
Historical price & volume chart
Step-by-step buying guide
Side-by-side peer comparison
Detailed investment thesis & outlook
Disclaimer: The information presented on this page is for informational and educational purposes only and does not constitute investment advice, financial advice, trading advice, or any other kind of advice. Cannabismarketcap does not recommend that any security be bought, sold, or held by you. All investments involve risk, and the past performance of a security, industry, sector, market, financial product, trading strategy, or individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. Cannabis stocks carry additional risks including federal illegality, regulatory uncertainty, limited banking access, and high volatility. Always conduct your own research and consider consulting a qualified financial advisor before making investment decisions.